Pulmonary Artery Pressure-Guided Therapy for Heart Failure Patients: Rationale and Challenges
An online educational activity based on a CME Satellite Symposium presented at the 20h Annual Meeting of the Heart Failure Society of America in Orlando, FL.
This activity is intended for cardiovascular specialists, cardiovascular nurses and nurse practitioners, pharmacists, scientist and other healthcare professionals caring for patients with heart failure.
Date of Release: December 1, 2016 Program End Date: November 30, 2017
Learning Objectives: Upon completion of this activity, participants will be able to:
Describe the importance of reducing elevated pulmonary artery (PA) pressures in patients with heart failure.
Identify interventions in response to PA pressure monitoring which can lead to decreased hospitalizations for heart failure.
Discuss the findings on the evaluation of cost-‐effectiveness for ambulatory PA pressure monitoring.
Identify situations in which therapy guided by PA pressure monitoring influences patient outcomes
Accreditation Statement Physician: The Heart Failure Society of America is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Designation Statement The Heart Failure Society of America designates this online activity for a maximum of 1.00 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Course Content - Pulmonary Artery Pressure-Guided Therapy for Heart Failure Patients: Rationale and Challenges
Welcome and Introduction of Speakers Maria Rosa Costanzo, Naperville, IL
Pulmonary Artery Pressure: Does it matter in heart failure patients? Liviu Klein, San Francisco, CA
Which Interventions Linked to Pulmonary Artery Pressure Measurements Lead to Improve Patient Outcomes? Akshay S. Desai, Boston, MA
Remote PA Pressure Monitoring: More Cost Effective or More Labor Intensive? William T. Abraham, Columbus, OH
Panel Q & A All Faculty
Disclosures As a provider accredited by ACCME, HFSA ensures balance, independence, objectivity and scientific rigor in its educational activities. Course Directors, planning committee members, and speakers are required to disclose all relevant financial relationships. Faculty will also disclose off‐label or investigational uses of pharmaceuticals or devices discussed in their presentations. All potential conflicts have been resolved in accordance with ACCME guidelines for commercial support and content validation.
Speaker Disclosures: William T. Abraham, MD indicated the following financial relationships: Consultant/Advisory: Novartis, St. Jude Medical, Zoll, Abbott
Maria Rosa Costanzo, MD indicated nothing to disclose.
Akshay S. Desai, MD, MPH indicated the following financial relationships: Research Grants: Novartis Speaking/Honoraria: Novartis, St. Jude Medical Consultant/Advisory: Novartis, Relypsa, St. Jude Medical, Merck, Janssen, Sanofi
Liviu Klein, MD, MS indicated the following financial relationships: Ownership Interest in ReThink Medical Consultant/Advisory: Medtronic, Boston Scientific, St. Jude Medical, ReThink Medical
HFSA Planner / Reviewer Disclosures: John Burnett, Jr., MD, has disclosed no relevant financial relationships.
Mona Fiuzat, PharmD, has disclosed no relevant financial relationships.
Gregg Fonarow, MD, has disclosed the following relevant financial relationships: Research Grants: National Institutes of Health (NIH). Consultant/Advisory Board : Amgen Inc.; Janssen Pharmaceuticals, Inc.; Medtronic; and Novartis Pharmaceuticals Corporation; St. Jude; and ZS Pharma
Kenneth Margulies, MD, has disclosed the following relevant financial relationships: Research Grants: CardioCell, LLC; Merk; Sharp and Dohme; and St. Lukes Hospital (Kansas City) Consultant/Advisory Board: GlaxoSmithKline; Merk; Janssen Pharmaceuticals, Inc.; and Sharp and Dohme.
Debra Moser, DNSc, RN, has disclosed no relevant financial relationships.
Marc Semigran, MD, has disclosed the following relevant financial relationships: Research Grants: CVRx. Inc.; St. Jude Medical; and Novartis Pharmaceuticals Corporation. Consultant/Advisory Board: Amgen Inc.; and Broadview.
David Whellan, MD, has disclosed no relevant financial relationships.
Jaime Abreu, MBA, has disclosed no relevant financial relationships.
Dawn Saterdalen, RN, MBA, has disclosed no relevant financial relationships.
Denise Broderick, BSc, has disclosed no relevant financial relationships.
Commercial Support Support for this enduring activity was provided through an independent educational grant from St. Jude Medical, Inc.
Method of Participation and CME Certificate The information provided in this CME activity is for continuing education purposes only and is not meant to substitute for the independent medical/clinical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient’s medical condition.
To receive CME credit for this product, the participant must:
Read the CME Information including target audience, learning objectives, and faculty disclosures.
Complete the pre-test.
View the presentations.
Complete the post-test and evaluation by choosing the best answer to each question. You must score 80% or higher on the post-test. You will have the opportunity to re-take questions missed until the 80% score is achieved.
After successfully completing the post-test and evaluation, your CME certificate will be generated and immediately available for print.
Medium or Combination of Media Used This enduring activity is available in these format offerings:
Online access via the HFSA Website under Online Education
Downloadable MP3 files
Mobile version for most mobile devices
Provider Contact information Heart Failure Society of America 6707 Democracy Blvd., Suite 925 Bethesda, MD 20817 Website: www.hfsa.org Email: firstname.lastname@example.org
Customer Support For support related to this site, please contact: email@example.com or Toll Free: 877‐796‐1325